Market Research Report
Sarcopenia - Pipeline Review, H1 2019
|Published by||Global Markets Direct||Product code||213093|
|Published||Content info||71 Pages
Delivery time: 1-2 business days
|Sarcopenia - Pipeline Review, H1 2019|
|Published: February 1, 2019||Content info: 71 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H1 2019, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.
Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength and function. Symptoms include weakness, loss of endurance and poor balance. Causes of sarcopenia include a reduction in the nerve cells, low hormone levels and decline in body's ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise and dietary supplements.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sarcopenia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Sarcopenia (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 1, 7, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.
Sarcopenia (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.